Brown Jeremy, Mook Piers, Vanhaverbeke Maarten, Gimma Amy, Hagan José, Singini Isaac, Avdičová Mária, Cullen Gillian, Dotsenko Liidia, Mossong Joël, Sadkowska-Todys Malgorzata, Suija Heelene, Bundle Nick, Pebody Richard
World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark.
The Regional Authority of Public Health in Banska Bystrica, Public Health Authority of the Slovak Republic.
Epidemiol Infect. 2025 Jan 6;153:e16. doi: 10.1017/S0950268824001833.
With the ongoing emergence of SARS-CoV-2 variants, there is a need for standard approaches to characterize the risk of vaccine breakthrough. We aimed to estimate the association between variant and vaccination status in case-only surveillance data. Included cases were symptomatic adult laboratory-confirmed COVID-19 cases, with onset between January 2021 and April 2022, reported by five European countries (Estonia, Ireland, Luxembourg, Poland, and Slovakia) to The European Surveillance System. Associations between variant and vaccination status were estimated using conditional logistic regression, within strata of country and calendar date, and adjusting for age and sex. We included 80,143 cases including 20,244 Alpha (B.1.1.7), 152 Beta (B.1.351), 39,900 Delta (B.1.617.2), 361 Gamma (P.1), 10,014 Omicron BA.1, and 9,472 Omicron BA.2. Partially vaccinated cases were more likely than unvaccinated cases to be Beta than Alpha (adjusted odds ratio [aOR] 2.48, 95% CI 1.29-4.74), and Delta than Alpha (aOR 1.75, 1.31-2.34). Fully vaccinated cases were relative to unvaccinated cases more frequently Beta than Alpha (aOR 4.61, 1.89-11.21), Delta than Alpha (aOR 2.30, 1.55-3.39), and Omicron BA.1 than Delta (aOR 1.91, 1.60-2.28). We found signals of increased breakthrough infections for Delta and Beta relative to Alpha, and Omicron BA.1 relative to Delta.
随着严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的不断出现,需要有标准方法来描述疫苗突破风险。我们旨在评估仅病例监测数据中变体与疫苗接种状态之间的关联。纳入的病例为有症状的成年实验室确诊的2019冠状病毒病病例,发病时间在2021年1月至2022年4月之间,由五个欧洲国家(爱沙尼亚、爱尔兰、卢森堡、波兰和斯洛伐克)向欧洲监测系统报告。在国家和日历日期分层内,使用条件逻辑回归评估变体与疫苗接种状态之间的关联,并对年龄和性别进行调整。我们纳入了80143例病例,包括20244例阿尔法(B.1.1.7)、152例贝塔(B.1.351)、39900例德尔塔(B.1.617.2)、361例伽马(P.1)、10014例奥密克戎BA.1和9472例奥密克戎BA.2。部分接种疫苗的病例感染贝塔变体的可能性高于未接种疫苗的病例感染阿尔法变体(调整后的优势比[aOR]为2.48,95%置信区间为1.29 - 4.74),感染德尔塔变体的可能性高于感染阿尔法变体(aOR为1.75,1.31 - 2.34)。与未接种疫苗的病例相比,完全接种疫苗的病例感染贝塔变体的频率更高(aOR为4.